Related Experiment Videos
Phenotype switch in acute leukemia patients after intensive chemotherapy
1Department of Internal Medicine, University Hospital Charité, Humboldt-Universität Berlin, German Democratic Republic.
Haematology and Blood Transfusion
|January 1, 1989
Summary
Lineage switch in acute leukemia occurs in 6.7%-8.6% of patients. Our cases showed myeloid-to-lymphoid switches, suggesting monitoring this phenomenon may guide leukemia treatment strategies.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute leukemia can exhibit lineage plasticity, a phenomenon where leukemic cells change their immunophenotype.
- Lineage switch, particularly lymphoid-to-myeloid conversion, is reported in 6.7%-8.6% of acute leukemia cases.
- This switch is often observed in relapsed or refractory leukemia, indicating a role in treatment resistance.
Observation:
- This study presents three cases of acute leukemia with observed lineage switches.
- Notably, two cases demonstrated a switch from myeloid to lymphoid phenotype, contrasting with the more commonly reported lymphoid-to-myeloid conversion.
- One case exhibited a lymphoid-to-myeloid phenotype switch.
Findings:
- The observed cases highlight the complexity of acute leukemia lineage plasticity.
- The frequency and direction of phenotype switching may differ from previously reported patterns.
- Chemotherapy's role in inducing or selecting for these switches is a key area of investigation.
Implications:
- Understanding lineage switch mechanisms is crucial for developing effective leukemia therapies.
- Monitoring phenotype changes during treatment could offer insights into treatment response and resistance.
- Further research is warranted to explore the clinical significance and therapeutic targeting of leukemia cell plasticity.